Evommune, Inc.
Evommune (NYSE: EVMN) is a clinical-stage biotechnology company developing therapies for chronic inflammatory diseases, with initial programs focused on chronic spontaneous urticaria, atopic dermatitis and ulcerative colitis. Its clinical pipeline includes EVO756, an oral small-molecule antagonist of MRGPRX2 being… From the company’s description.
In fiscal 2025, Evommune, Inc. reported revenue of $13.00M and a net loss of $68.87M. Its operating margin was −623.6%, and operations used $76.44M in cash.
Dotted labels explain each measure.
What Evommune, Inc. does
In the company’s own words
Evommune (NYSE: EVMN) is a clinical-stage biotechnology company developing therapies for chronic inflammatory diseases, with initial programs focused on chronic spontaneous urticaria, atopic dermatitis and ulcerative colitis. Its clinical pipeline includes EVO756, an oral small-molecule antagonist of MRGPRX2 being developed to modulate mast cells and peripheral sensory neurons, and EVO301, a long-acting fusion protein that targets the IL-18 inflammatory pathway. EVO756 is in Phase 2b development for urticaria and atopic dermatitis, while EVO301 is being developed for atopic dermatitis, with ulcerative colitis also under evaluation. The company is advancing additional preclinical programs in immunology and inflammation and is exploring further indications, including migraine, asthma and Crohn’s disease. Evommune licensed exclusive global development and commercialization rights to EVO301 from South Korea’s AprilBio in 2024. Its website is https://www.evommune.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- PALO ALTO, CA
- Fiscal year end
- December
- CIK
- 2044725
- SIC
- 2834
Financial performance, year by year
Fiscal 2025–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Evommune, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Evommune, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Evommune, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Evommune, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Evommune, Inc.'s last four quarterly filings that the numbers alone won't show?”